BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 2,000 shares of the firm's stock in a transaction on Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares in the company, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BridgeBio Pharma Stock Down 1.3%
Shares of BBIO opened at $74.03 on Wednesday. BridgeBio Pharma, Inc. has a one year low of $60.22 and a one year high of $93.42. The business has a fifty day moving average of $70.00 and a 200 day moving average of $72.80.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. During the same period in the prior year, the company posted ($0.95) EPS. The firm's revenue was up 192.6% compared to the same quarter last year. On average, research analysts predict that BridgeBio Pharma, Inc. will post -2.59 EPS for the current year.
Hedge Funds Weigh In On BridgeBio Pharma
A number of institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC grew its holdings in BridgeBio Pharma by 139.4% during the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company's stock valued at $2,431,000 after purchasing an additional 19,043 shares during the period. Assetmark Inc. increased its position in BridgeBio Pharma by 423.7% in the first quarter. Assetmark Inc. now owns 20,790 shares of the company's stock worth $1,544,000 after buying an additional 16,820 shares in the last quarter. EFG International AG bought a new position in shares of BridgeBio Pharma in the second quarter worth about $6,117,000. Corient Private Wealth LP bought a new position in shares of BridgeBio Pharma in the second quarter worth about $1,783,000. Finally, Squarepoint Ops LLC raised its stake in shares of BridgeBio Pharma by 114.2% in the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company's stock worth $88,760,000 after buying an additional 635,408 shares during the period. 99.85% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts have recently commented on the stock. Citigroup reduced their price target on shares of BridgeBio Pharma from $94.00 to $91.00 and set a "neutral" rating for the company in a research report on Monday, October 19th. Barclays dropped their price objective on shares of BridgeBio Pharma from $157.00 to $156.00 and set an "overweight" rating on the stock in a report on Wednesday, October 7th. Piper Sandler raised their price objective on shares of BridgeBio Pharma from $115.00 to $120.00 and gave the stock an "overweight" rating in a report on Monday, October 19th. HC Wainwright restated a "buy" rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Finally, Bank of America upped their target price on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Nineteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma has a consensus rating of "Moderate Buy" and an average price target of $104.26.
Check Out Our Latest Stock Report on BridgeBio Pharma
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.
BridgeBio's portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
